KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $159.6 million.

  • Neogenomics' Cash & Equivalents fell 5650.88% to $159.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $159.6 million, marking a year-over-year decrease of 5650.88%. This contributed to the annual value of $159.6 million for FY2025, which is 5650.88% down from last year.
  • As of Q4 2025, Neogenomics' Cash & Equivalents stood at $159.6 million, which was down 5650.88% from $164.1 million recorded in Q3 2025.
  • Neogenomics' 5-year Cash & Equivalents high stood at $612.0 million for Q1 2021, and its period low was $154.7 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $311.5 million (2021), whereas its average is $310.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 60949.75% in 2021, then plummeted by 5650.88% in 2025.
  • Over the past 5 years, Neogenomics' Cash & Equivalents (Quarter) stood at $316.8 million in 2021, then dropped by 16.93% to $263.2 million in 2022, then surged by 30.13% to $342.5 million in 2023, then rose by 7.16% to $367.0 million in 2024, then tumbled by 56.51% to $159.6 million in 2025.
  • Its Cash & Equivalents stands at $159.6 million for Q4 2025, versus $164.1 million for Q3 2025 and $154.7 million for Q2 2025.